Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. We report on a novel nonsense mutation that leads to exon skipping and the activation of a cryptic exon. Screening of genomic DNA from 700 German patients with CF uncovered four cases with the nonsense mutation E92X, a G --T transversion that creates a termination codon and affects the first base of exon 4 ofthe CFTR gene. Lymphocyte RNA oftwo CF patients heterozygous for E92X was found to contain the wild type sequence and a differentially spliced isoform lacking exon 4. In RNA derived from nasal epithelial cells of E92X patients, a third fragment of longer size was observed. Sequencing revealed the presence of E92X and an additional 183-bp fragment, inserted between exons 3 and 4. The 183-bp sequence was mapped to intron 3 of the CFTR gene. It is flanked by acceptor and donor splice sites. We conclude that the 183-bp fragment in intron 3 is a cryptic CFI'R exon that can be activated in epithelial cells by the presence of the E92X mutation. E92X abolishes correctly spliced CFI`R mRNA and leads to severe cystic fibrosis. (J.
Introduction
Cystic fibrosis (CF)I is the most common severe autosomal recessive disorder in Caucasian populations. In CF patients, altered chloride transport across the apical membrane ofepithelial cells is associated with the accumulation of abnormal mucus in lung and pancreas resulting in chronic obstructive lung disease and pancreatic insufficiency ( 1, 2) . The gene af- 1 . Abbreviations used in this paper: CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; SSCP, single strand conformation polymorphism. fected in CF, the cystic fibrosis transmembrane conductance regulator (CFTR), spans -250 kb on chromosome 7q3 1 and comprises 27 exons (3, 4) , encoding a cAMP-and ATP-regulated low conductance chloride channel (5) . In addition to the major mutation, AF508 (6) , > 300 further mutations within the CFTR gene have been identified (Cystic Fibrosis Genetic Analysis Consortium, August 1993) . These mutations have been shown to cause mRNA deficiency (7-1 1), aberrant splicing (12) (13) (14) , defective maturation of the protein ( 15, 16) , and the alteration or loss of chloride channel function ( 17, 18) . In this study, we have identified and characterized a novel nonsense mutation, E92X, that affects the first nucleotide of exon 4, thereby leading to exon skipping and the insertion ofa previously unknown cryptic exon into epithelial CFTR mRNA. Case reports of four German patients and the result of transcript analyses indicate that the E92X nonsense mutation causes severe CF because it abolishes correct splicing of the CFTR mRNA.
Methods
Samples. Peripheral blood samples were taken from 700 CF patients of German origin after informed consent had been obtained, and genomic DNA was extracted by standard procedures. Each DNA sample was routinely screened for the presence ofthe most common mutations as previously described ( 19, 20) . Samples with at least one unidentified mutation were subjected to single strand conformation polymorphism (SSCP) analysis. Human pancreas total RNA was obtained from Clontech (Palo Alto, CA). Colon cell lines T84 and HT-29 were cultured as described previously (21 ) .
SSCP Analysis (22 (24) . With primer CF704, 5 Ag of lymphocyte RNA or the total yield ofepithelial RNA were converted to cDNA using a First-Strand-cDNA-Synthesis Kit (Pharmacia, Upsala, Sweden) according to the manufacturer's protocol.
CFTR cDNA spanning exons 3-5 was amplified using the nested PCR approach depicted in Fig. 2 . The sequences of PCR primers are listed in Table I . Aliquots of the final PCR were analyzed in a 2% low melting agarose gel. Bands were cut out, melted, and reamplified using the biotinylated primer B-CF297 and primer CFG 178. Single strands for direct sequencing were obtained with biotin streptavidin magnetic beads (Dynal, Oslo, Norway) according to the manufacturer's protocol. Either primers CFG 178 or CF740 were used for direct sequencing by the dideoxy chain termination method using the Sequenase 2.0 kit (U. S. Biochem. Corp., Cleveland, OH).
Southern blot hybridization (25) . 20 ,ug of genomic DNA was digested using the restriction enzyme EcoRI, subjected to electrophoresis through a 0.8% agarose gel, and blotted onto N+ Nylon membrane (Amersham Buckinghamshire, UK) using 0.4 N NaOH. The filter was hybridized with the insert DNA amplified from genomic DNA using primers 183-5' and 183-3' (Table I) and labeled by the random primelabeling method (26) with a--[32P]dCTP (Amersham). Overnight hybridization at 65°C was followed by two washes in 2X SSC, 0.1% SDS at room temperature, two washes at 55°C with the same solution, and a final wash with a 0.5X SSC, 0.1 % SDS solution at 55°C.
Vectorette PCR (27) . To (Fig. 4, Table I ). After the third PCR, sequencing was performed using a combination of the biotin streptavidin magnetic beads method and the dideoxy chain termination method mentioned above.
The 3' end sequence ofthe 183-bp fragment was confirmed by PCR and direct sequencing using primers B 183-8 and 183-10, created from the downstream sequence of the 183-bp fragment.
Allele-specific oligonucleotide hybridization (28) . 10% of the total RT-PCR (Fig. 2 ) was subjected to electrophoresis through a 0.8% agarose gel stained with ethidium bromide and were blotted onto N+ Nylon membrane (Amersham) using 0.4 N NaOH. The hybridization with Y_-[32P]dATP-labeled oligonucleotide CFN3 (GATAGAGAG-CTGGCT) at 48°C 3 h was followed by two washes in 2X SSPE, 0.1% Triton X-100 at room temperature, and two washes at 58°C with the same solution. The x-ray film was analyzed by densitometry. 
Results
The investigation of PCR products from genomic DNA of 700 German CF patients by single-strand conformation analysis and direct sequencing led to the identification of a novel nonsense mutation E92X in exon 4 of the CFTR gene ( Fig. 1) . This G -* T transversion at the first base ofexon 4 was detected in three families from Southern Germany with four CF patients. The clinical data of all four patients are summarized in Table II. In family 1, an E92X/ AF508 compound heterozygous female was severely affected throughout her life. Since infancy she exhibited pathognomic CF symptoms such as steatorrhea, In all three families, the E92X chromosome is characterized by an uncommon combination ofthe extragenic upstream marker haplotype 1-2-2-1 (XV2c-KM. 19-MP6D9-J44) and the intragenic CFTR marker haplotype 1-2-2-1-1 (GATT-TUB9-M470V-T854-TUB18), which could have evolved by recombination from the two most common dimorphic marker haplotypes in German families (19). This infrequent haplotype was not seen in other German CF chromosomes in our panel, suggesting that it could be diagnostic for the E92X mutation probably due to a founder effect. This hypothesis is further strengthened by the common geographic origin of all three families from the same small area of Southern Germany. As expected from the haplotype data, an additional screening for E92X with the restriction enzyme EcoNI did not uncover further cases among 800 German CF chromosomes tested this way.
Since the E92X mutation affects the first nucleotide ofexon 4, we surmised a possible effect on the splicing of CFTR pre- (Fig. 2) . Direct sequencing ofthe excised RT-PCR product from all three probands showed the wild type sequence without the E92X mutation in the 39 1-bp product, thus demonstrating skipping of exon 4 in the 175-bp product (Fig. 3) . This exon skipping was neither observed in 10 further lymphocyte samples from healthy control persons nor in the paternal lymphocyte sample. A different pattern was obtained from nasal epithelial cells of the patients and their mother, which gave an additional product of 574 bp (Fig. 2) larger RT-PCR product was neither found in pancreas or other previously analyzed (21 ) control tissues from non-CF individuals, nor in the colon cell lines HT-29 or T84. The aberrantly spliced mRNA was found to be transcribed only from the E92X allele (Fig. 3 D) and contains two in-frame nonsense codons (Fig. 4 C) . We confirmed the human origin ofthe 1 83-bp insert by PCR from genomic DNA using primers located within the inserted sequence (183-5' and 183-3'). Assuming the 183-bp insert to be the result of a splicing event within intron 3 ofthe CFTR gene, PCR with primers specific to exon 3 and the insert was performed from genomic DNA, resulting in amplification of a 2.7-kb fragment. Direct sequencing of this PCR product showed the 183-bp sequence to be located -2.2 kb downstream of exon 3 and to be preceded by an acceptor splice site with a short pyrimidine stretch (Fig. 4  A) . With additional sequencing primers, we obtained further sequence information from -300 bp of the 3' splice site preceding the inserted sequence (Fig. 4 C) . Since most branch points are located within 18-40 bp from the 3' splice junction (30), two possible branch points are favored (Fig. 4 C) . Interestingly, an apparently more perfect branch point sequence is located further upstream of the new 1 83-bp exon followed by another apparently silent 3' splice site with a longer polypyrimidine stretch. In addition, this part of intron 3 seems highly repetitive.
For the determination of downstream sequences, we used Vectorette PCR as recently described (27) . Southern blot analysis of genomic DNA using the insert sequence as a probe guided the choice of the appropriate Vectorette unit. Since the 183-bp insert hybridized to an -4.5-kb EcoRI fragment, we constructed a genomic EcoRI Vectorette library and conducted nested PCR with primers specific to the 183-bp exon and the Vectorette unit (Fig. 4 B) . Direct sequencing of the final PCR product revealed a perfect donor splice site flanking the 183-bp exon (Fig. 4 C) . We then established intron primers for the amplification of the whole new exon and its flanking intron sequences (Table I) . SSCP analysis and direct sequencing of genomic DNA from the patients and 10 further individuals harboring different CFTR haplotypes did not show any polymorphisms or sequence variants in the analyzed region. ment and its surroundings in intron 3 of the CFTR gene. The 183-bp fragment (enclosed by brackets), containing two stop codons (bold letters, underlined), is flanked by perfect 5' and 3' splice sites with a short oligopyrimidine stretch (bold letters). Two candidate sequences for the branch point are underlined. A silent 3' splice site with a large polypyrimidine stretch and a perfect branch point is located further upstream of the 183-bp exon (underlined with dashes). The deduced amino acid sequence for the cryptic exon (until the stop codon) is shown above the nucleotide sequence in a single-letter code. These data were submitted to the LANL Database under accession number L25269.
Finally, we found no sequence homology of this cryptic exon least one pancreas-sufficient allele (32, 33) . Following that clasand the deduced peptide to other genes or proteins, respec-sification, the E92X mutation is a pancreas-insufficient allele, tively.
because the E92X/AF508 patient was pancreas insufficient since infancy. The It has, however, been shown that the onset of many clinical CF with E92X is the first case of a human inherited disease, symptoms, including pancreatic insufficiency and airways' co-as far as we know, in which the consequences of a change ofthe lonization with opportunistic pathogens, is partly determined first nucleotide of an exon were studied in patients' mRNA by the CFTR mutation genotype (31) (32) (33) , which appears to be transcripts. This G --T transversion affects the 3' splice site of the main factor in the genetic predisposition for CF. CFTR exon 4 and furthermore creates an in-frame stop codon. RTmutations have been classified according to their effect on pan-PCR analyses indicated the ability of this mutation to induce creatic function as pancreas insufficient ("severe") or pancreas exon 4 skipping of the transcripts (lymphocytes and nasal episufficient ("mild") alleles, and by this definition the mainte-thelial cells) as well as activation ofa cryptic splice site in intron nance of pancreatic function in CF requires the presence of at 3, resulting in the inclusion of an additional 183-bp fragment.
The 183-bp sequence was present in nasal epithelial cell-derived mRNA of the two E92X heterozygous probands. As shown by direct sequencing (Fig. 3 D) , it was only transcribed from the E92X allele. There was no evidence for use of the cryptic splice sites in CFTR transcripts of lymphocytes from patients and several controls. Furthermore, the cryptic exon has never been detected in kidney, liver, jejunum, placenta, lung, and nasal polyps from non-CF controls (21 ) .
The differences in the splicing pattern of E92X transcripts, identical in all analyzed specimens, point to a tissue-specific splicing event. Since differential expression of various cis-acting elements and trans-acting factors have been reported to be involved in determination of tissue or developmental stage specificity (34) (35) (36) , it is not unexpected that a mutation ofthe 3' splice site sequence may lead to different splicing patterns in ectopic and expressing tissues. However, no further cases of tissue-specific splicing of CFTR transcripts are known to date.
Normally spliced CFTR transcripts carrying the E92X mutation were not observed in both tissues. Several reports of severely reduced mRNA levels as a consequence of nonsense mutations in the CFTR gene have been published (7-9, 1 1), but in case ofthe E92X mutation, densitometric quantification of ASO-hybridized PCR products suggests that the main effect ofthis mutation is aberrant splicing. However, we cannot completely exclude normally spliced but reduced proportions of transcripts from E92X-carrying alleles, because the yield of PCR products could have been biased by the cDNA size in nested PCR.
The observed in-frame-skipping of exon 4 and the severity ofthe E92X allele would be consistent with a proposed important role ofexon 4 for CFTR function. Skipping ofexon 4 from CFTR transcripts has been reported in humans (21 ) and mice (37) , but exon 4-transcripts represented only a very small proportion of total CFTR mRNA from human tissues (21), and did not appear to be associated with clinical symptoms. Exon skipping does not always cause disease; nonsense mutation-induced exon skipping has even been shown to function as a mechanism for phenotypic rescue of the common inherited defect of the AMPD1 (AMP deaminase) gene (38) . Such a phenotypic rescue in case of the E92X mutation can probably not be realized by omission ofexon 4, given the severe clinical course in the AF508/E92X compound heterozygous patient, the high number of other known disease-causing CF mutations affecting this exon (29) , and the postulated role of exon 4 in coding for a large part of the CFTR transmembrane pore (3). Even if residual functions ofexon 4 -CFTR have not been excluded by in vitro experiments so far, parallels can be drawn from the frequent splice site mutation 621 + 1 G --T, which also leads to skipping of exon 4 (13, 39) . A comprehensive genotype-phenotype study of patients carrying the splice mutation 621 + 1 G --T strongly argues that the extensive exon 4 skipping is associated with an early onset ofsevere clinical symptoms of CF (40) . In the E92X patients, the fraction of exon 4 skipping has been relatively low in epithelial cells compared with the proportion of the in-frame cryptic exon inclusion. The inserted cryptic exon, however, by itself introduces two new nonsense codons into the E92X transcript, and its translation would lead to a severely truncated protein containing only 7% of wild type CFTR.
Cryptic (45, 47) . Furthermore, it is noteworthy that the E92X allele was found exclusively in conjunction with the cryptic 1 83-bp exon. Exon 3b was not seen in normal controls, and E92X did not appear within a normally spliced product. A possible interpretation of this observation is that both the donor splice site of cryptic exon 3b and the weakened acceptor splice site with E92X are only used if they can be recognized together, and this recognition appears to be tissue specific. Alternatively, epithelial cells may generally use the cryptic exon in a first splicing step, but its subsequent removal may be disturbed by the presence of E92X within the acceptor splice site. The exon sequence adjacent to the invariant consensus sequence has been shown to be a determinant for splice site selection in natural pre-mRNAs as well as in artificial constructs (48, 49) , and consequently exon mutations as E92X can change the relative strength of competing splice sites, resulting in aberrant splicing. Furthermore, a single base mutation can have long-range effects on the concerted splicing of other exons, leading to multiple exon skipping (50) . Besides several cis-acting elements, various antagonistic splicing factors such as SF2 and ASF, and heterogeneous nuclear ribonucleoproteins such as hnRNP Al appear to be involved in the tissue specificity of splicing ( 51 ) . Future characterization of cis-and trans-acting factors and of their spatial and temporal interaction will improve our understanding of the role of splice site selection in differentiation and disease.
